• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

从临床样本中生成肺腺癌类器官的方案。

Protocol for generation of lung adenocarcinoma organoids from clinical samples.

机构信息

Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong 518035, China.

International Cancer Center, Shenzhen University School of Medicine, Shenzhen, Guangdong 518060, China.

出版信息

STAR Protoc. 2020 Dec 28;2(1):100239. doi: 10.1016/j.xpro.2020.100239. eCollection 2021 Mar 19.

DOI:10.1016/j.xpro.2020.100239
PMID:33426535
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7779824/
Abstract

Human cancer tissue-derived organoids maintain the mutational spectrum and histological characteristics of their parental tumors and thus provide a platform for predicting patients' responses to anticancer drugs. Here, we provide a fully detailed, step-by-step protocol to derive lung adenocarcinoma organoids from primary tumor tissues. Organoid lines can be generated with a success rate of 80% using our protocol. For complete details on the use and execution of this protocol, please refer to Li et al. (2020).

摘要

人源肿瘤组织衍生类器官保留了其亲本肿瘤的突变谱和组织学特征,因此为预测患者对抗癌药物的反应提供了一个平台。在此,我们提供了一个从原发性肿瘤组织中获得肺腺癌类器官的详细、全面的分步方案。使用我们的方案,类器官系的生成成功率可达 80%。有关该方案使用和执行的完整详细信息,请参考 Li 等人(2020 年)。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd18/7779824/5166e123b4e6/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd18/7779824/9219dfbf36f0/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd18/7779824/276e8980c4f5/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd18/7779824/b0cdc896f213/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd18/7779824/15a818951ffc/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd18/7779824/434f5c4be98e/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd18/7779824/5166e123b4e6/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd18/7779824/9219dfbf36f0/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd18/7779824/276e8980c4f5/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd18/7779824/b0cdc896f213/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd18/7779824/15a818951ffc/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd18/7779824/434f5c4be98e/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd18/7779824/5166e123b4e6/gr5.jpg

相似文献

1
Protocol for generation of lung adenocarcinoma organoids from clinical samples.从临床样本中生成肺腺癌类器官的方案。
STAR Protoc. 2020 Dec 28;2(1):100239. doi: 10.1016/j.xpro.2020.100239. eCollection 2021 Mar 19.
2
Oncogenic potential of human pluripotent stem cell-derived lung organoids with HER2 overexpression.HER2 过表达的人多能干细胞衍生肺类器官的致癌潜力。
Int J Cancer. 2021 Oct 15;149(8):1593-1604. doi: 10.1002/ijc.33713. Epub 2021 Jul 7.
3
Normal and tumor-derived organoids as a drug screening platform for tumor-specific drug vulnerabilities.正常和肿瘤类器官作为肿瘤特异性药物脆弱性的药物筛选平台。
STAR Protoc. 2022 Jan 10;3(1):101079. doi: 10.1016/j.xpro.2021.101079. eCollection 2022 Mar 18.
4
Obtaining patient-derived cancer organoid cultures via fine-needle aspiration.通过细针抽吸获取患者来源的癌症类器官培养物。
STAR Protoc. 2020 Dec 21;2(1):100220. doi: 10.1016/j.xpro.2020.100220. eCollection 2021 Mar 19.
5
Generation of Pancreatic Organoid-Derived Isografts.生成胰腺类器官衍生同系移植物。
STAR Protoc. 2020 Jun 6;1(2):100047. doi: 10.1016/j.xpro.2020.100047. eCollection 2020 Sep 18.
6
Genotype-phenotype mapping of a patient-derived lung cancer organoid biobank identifies NKX2-1-defined Wnt dependency in lung adenocarcinoma.患者衍生肺癌类器官生物库的基因型-表型图谱分析确定肺腺癌中 NKX2-1 定义的 Wnt 依赖性。
Cell Rep. 2023 Mar 28;42(3):112212. doi: 10.1016/j.celrep.2023.112212. Epub 2023 Mar 6.
7
Protocol for derivation of organoids and patient-derived orthotopic xenografts from glioma patient tumors.从胶质瘤患者肿瘤中衍生类器官和患者来源的原位异种移植物的方案。
STAR Protoc. 2021 May 12;2(2):100534. doi: 10.1016/j.xpro.2021.100534. eCollection 2021 Jun 18.
8
Protocol for the generation of cultured cortical brain organoid slices.培养皮层脑类器官切片的方案。
STAR Protoc. 2024 Sep 20;5(3):103212. doi: 10.1016/j.xpro.2024.103212. Epub 2024 Aug 10.
9
Immunofluorescent staining of cancer spheroids and fine-needle aspiration-derived organoids.免疫荧光染色的肿瘤球体和细针抽吸衍生类器官。
STAR Protoc. 2021 May 31;2(2):100578. doi: 10.1016/j.xpro.2021.100578. eCollection 2021 Jun 18.
10
Modeling diverse genetic subtypes of lung adenocarcinoma with a next-generation alveolar type 2 organoid platform.利用下一代肺泡 II 型类器官平台对肺腺癌的多种遗传亚型进行建模。
Genes Dev. 2022 Aug 1;36(15-16):936-949. doi: 10.1101/gad.349659.122. Epub 2022 Sep 29.

引用本文的文献

1
Respiratory microphysiological system in respiratory research: recent advances and future prospects.呼吸研究中的呼吸微生理系统:最新进展与未来展望。
Respir Res. 2025 Jul 26;26(1):253. doi: 10.1186/s12931-025-03327-1.
2
Evaluation of In Vitro Cytotoxic Activity of CAR-T Cells Using Patient-Derived Organoids.使用患者来源类器官评估CAR-T细胞的体外细胞毒性活性
Bio Protoc. 2025 Jul 5;15(13):e5369. doi: 10.21769/BioProtoc.5369.
3
Establishing 3D organoid models from patient-derived conditionally reprogrammed cells to bridge preclinical and clinical insights in pancreatic cancer.

本文引用的文献

1
Human Lung Adenocarcinoma-Derived Organoid Models for Drug Screening.用于药物筛选的人肺腺癌来源类器官模型
iScience. 2020 Aug 21;23(8):101411. doi: 10.1016/j.isci.2020.101411. Epub 2020 Jul 25.
2
Challenges in Establishing Pure Lung Cancer Organoids Limit Their Utility for Personalized Medicine.建立纯肺癌类器官面临的挑战限制了它们在个性化医疗中的应用。
Cell Rep. 2020 May 5;31(5):107588. doi: 10.1016/j.celrep.2020.107588.
3
Long-term expanding human airway organoids for disease modeling.长期扩增的人呼吸道类器官用于疾病建模。
利用患者来源的条件重编程细胞建立3D类器官模型,以弥合胰腺癌临床前和临床见解之间的差距。
Mol Cancer. 2025 Jun 3;24(1):162. doi: 10.1186/s12943-025-02374-y.
4
Addition of metformin to anti-PD-1/PD-L1 drugs activates anti-tumor immune response in peripheral immune cells of NSCLC patients.在抗PD-1/PD-L1药物中添加二甲双胍可激活非小细胞肺癌患者外周免疫细胞中的抗肿瘤免疫反应。
Cell Death Dis. 2025 Apr 13;16(1):286. doi: 10.1038/s41419-025-07636-7.
5
Lung cancer organoids: a new strategy for precision medicine research.肺癌类器官:精准医学研究的新策略。
Transl Lung Cancer Res. 2025 Feb 28;14(2):575-590. doi: 10.21037/tlcr-24-921. Epub 2025 Feb 18.
6
Lung cancer organoid-based drug evaluation models and new drug development application trends.基于肺癌类器官的药物评估模型及新药开发应用趋势
Transl Lung Cancer Res. 2024 Dec 31;13(12):3741-3763. doi: 10.21037/tlcr-24-603. Epub 2024 Dec 24.
7
Preclinical Models for Functional Precision Lung Cancer Research.用于功能性精准肺癌研究的临床前模型
Cancers (Basel). 2024 Dec 25;17(1):22. doi: 10.3390/cancers17010022.
8
Patient-derived organoids and mini-PDX for predicting MET-mutated lung cancer patient clinical therapeutic response.用于预测MET突变型肺癌患者临床治疗反应的患者来源类器官和微型患者来源肿瘤异种移植模型
Heliyon. 2024 Sep 12;10(18):e37884. doi: 10.1016/j.heliyon.2024.e37884. eCollection 2024 Sep 30.
9
Recent advances in lung cancer organoid (tumoroid) research (Review).肺癌类器官(肿瘤类器官)研究的最新进展(综述)
Exp Ther Med. 2024 Aug 1;28(4):383. doi: 10.3892/etm.2024.12672. eCollection 2024 Oct.
10
iPSC-derived lung and lung cancer organoid model to evaluate cisplatin encapsulated autologous iPSC-derived mesenchymal stromal cell-isolated extracellular vesicles.用于评估顺铂包裹的自体诱导多能干细胞衍生的间充质基质细胞分离的细胞外囊泡的诱导多能干细胞衍生的肺和肺癌类器官模型
Stem Cell Res Ther. 2024 Aug 7;15(1):246. doi: 10.1186/s13287-024-03862-6.
EMBO J. 2019 Feb 15;38(4). doi: 10.15252/embj.2018100300. Epub 2019 Jan 14.
4
A Comprehensive Human Gastric Cancer Organoid Biobank Captures Tumor Subtype Heterogeneity and Enables Therapeutic Screening.一个全面的人类胃癌类器官生物库捕获了肿瘤亚型异质性,并能够进行治疗筛选。
Cell Stem Cell. 2018 Dec 6;23(6):882-897.e11. doi: 10.1016/j.stem.2018.09.016. Epub 2018 Oct 18.
5
Human primary liver cancer-derived organoid cultures for disease modeling and drug screening.用于疾病建模和药物筛选的人原发性肝癌来源的类器官培养物。
Nat Med. 2017 Dec;23(12):1424-1435. doi: 10.1038/nm.4438. Epub 2017 Nov 13.
6
The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification.2015 年世界卫生组织肺肿瘤分类:自 2004 年分类以来遗传、临床和放射学进展的影响。
J Thorac Oncol. 2015 Sep;10(9):1243-1260. doi: 10.1097/JTO.0000000000000630.
7
ΔNp63 (p40) and thyroid transcription factor-1 immunoreactivity on small biopsies or cellblocks for typing non-small cell lung cancer: a novel two-hit, sparing-material approach.ΔNp63(p40) 和甲状腺转录因子-1 免疫反应在小活检或细胞块上用于非小细胞肺癌分型:一种新的两击、节约材料的方法。
J Thorac Oncol. 2012 Feb;7(2):281-90. doi: 10.1097/JTO.0b013e31823815d3.
8
Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift.基于小活检和细胞学检查的晚期肺癌病理诊断:范式转变
J Thorac Oncol. 2010 Apr;5(4):411-4. doi: 10.1097/JTO.0b013e3181d57f6e.